Enterprise reports phase 2 cystic fibrosis win, succeeding where Big Pharma stumbled
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that compa...
A phase 2 trial of Enterprise Therapeutics’ cystic fibrosis drug candidate has hit its primary endpoint, furthering the biotech’s pursuit of a target that companies including Vertex have worked on previously.